Description
Linvesta-EMP 5/10 Tablets combine two medications: linagliptin and empagliflozin, used to manage type 2 diabetes mellitus. Linagliptin is a DPP-4 inhibitor that helps increase insulin production and decrease glucose production in the liver. Empagliflozin is an SGLT2 inhibitor that promotes the excretion of glucose through the urine, reducing blood sugar levels.
Dosage/Direction:
The standard dose is 1 tablet (5/10) once daily, typically in the morning, with or without food. The dosage may be adjusted based on blood sugar levels and individual response. It is important to follow your healthcare provider’s instructions for dosage and monitor blood glucose levels regularly.
Side Effects:
Common side effects include urinary tract infections, increased urination, and gastrointestinal symptoms. Rare but serious side effects may include ketoacidosis, severe dehydration, or kidney issues. Consult your healthcare provider if you experience any severe or unusual symptoms.
